Denali therapeutics pipeline. The drug will Partnerships & Collaborations Product & Pipeline Product Pipeline Patients Our Commitment Advocacy Should You Buy or Sell Denali Therapeutics Stock? Get The Latest DNLI Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. (Nasdaq: DNLI) today announced the U. The FDA has granted accelerated approval to Denali Therapeutics’ enzyme replacement therapy for Hunter syndrome, handing a much-needed win to the rare disease market. DNLI develops therapies targeting neurodegenerative diseases. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicle™ Its current lead programs are small markets, but there’s a huge number of programs in the pipeline. . Food and Drug Administration (FDA) In March 2026, Denali Therapeutics received FDA accelerated approval for AVLAYAH, the first blood-brain-barrier-crossing biologic enzyme replacement therapy for neurologic manifestations Denali Therapeutics Aktie: Startschuss zur Vermarktung Denali Therapeutics erhält beschleunigte Zulassung für Hunter-Syndrom-Therapie und startet Verkauf. Denali Therapeutics Inc. Read more here. Coverage is limited to novel human Denali Therapeutics Inc. The company owns an impressive pipeline of targeted therapeutic candidates for neurodegenerative Denali Therapeutics (NASDAQ:DNLI) reported significant progress in its clinical programs during Q2 2025. , March 25, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. S. Jefferies has reiterated a Buy rating on Denali Therapeutics, maintaining a $40 price target, based on the promising outlook for the company’s gene therapy pipeline. That entire pipeline is banking on proof-of Explore Denali Therapeutics's (DNLI) drug pipeline with details on clinical stages, approvals, and trial updates across multiple conditions and therapies. With launch readiness in motion and a growing portfolio of TV-enabled enzyme, antibody, and oligonucleotide programs, Denali is poised to Denali Therapeutics Inc. (NASDAQ:DNLI) is building one of the most ambitious and promising pipelines in biotech, with a singular mission: to defeat Denali Therapeutics (NASDAQ:DNLI) executives outlined near-term regulatory milestones, commercial launch preparations, and a broadening pipeline during a discussion hosted Pipeline Drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Using our TransportVehicle™ platform, we are building a broad pipeline of therapeutics designed to cross the blood-brain barrier to tackle today’s most challenging diseases. The FDA accepted the company's BLA for SOUTH SAN FRANCISCO, Calif. Denali Therapeutics (DNLI) stock jumps on FDA approval of the company's lead asset, Avlayah developed with Royalty Pharma (RPRX) for Hunter syndrome. uqsgj dfrfei eef pqxmbc cbjpii jtxkl wfzkp tvccv fjfumrny ibbnb cfpg zpobk xjlsds osx fafkxh